Intended for Healthcare Professionals

Newsroom

Stay up to date with the latest REVERSE-IT trial newsletters, webinars, and press releases.

NEWSLETTER MONTHLY WEBINARS PRESS RELEASES

August 2021 Newsletter

Vol.6

April 2021 Newsletter

Vol.5

March 2021 Newsletter

Vol. 4

December 2020 Newsletter

Vol.3

November 2020 Newsletter

Vol. 2

October 2020 Newsletter

Vol. 1

September 2021 Monthly Site Webex

North America Read More
EU Read More

September 16, 2021

July 2021 Monthly Site Webex

July 15, 2021

April 2021 Monthly Site Webex

April 22, 2021

March 2021 Monthly Site Webex

March 18, 2021

February 2021 Monthly Site Webex

February 18, 2021

December 2020 Monthly Site Webex

January 21, 2021

November 2020 Monthly Site Webex

November 24, 2020

January 2020 Monthly Site Webex

January 21, 2020

PhaseBio Announces Interim Analysis of REVERSE-IT Phase 3 Trial Accepted for Late Breaking Science Presentation at the American Heart Association Scientific Sessions 2021

October 06, 2021

PhaseBio Pharmaceuticals Achieves Enrollment Milestones Supporting Interim Analysis of REVERSE-IT Global Phase 3 Trial, Enabling Preparation of a BLA submission for Bentracimab for Reversal of Antiplatelet Effects of Ticagrelor

August 12, 2021

PhaseBio Announces Dosing of First Patient in European Union as Part of REVERSE-IT Global Phase 3 Trial of Bentracimab for Reversal of Antiplatelet Effects of Ticagrelor

January 28, 2021

Copyright © 2002-2020 PhaseBio. All rights reserved. This information—including product information—is intended only for residents of the United States. The products discussed herein may have different labeling in different countries.